Next-generation sequencing (NGS) has evolved rapidly over the last decade, and as a result, has revolutionised genomic research.
The last 2 years have propelled genomics into the spotlight. In January 2020, the WHO published their first Disease Outbreak News on a virus that had originated from Wuhan in China. A few days later, the genetic sequence of COVID-19 was shared publicly. Since then, the entire world’s population has been made aware of DNA sequencing and why it is so important for the future of human health. In addition, soon-to-expire patents and increasing competition within the sequencing market is expected to revitalise the NGS space in the next few years.
Compared to previous editions, what’s different about this report? Firstly, we have obtained a wealth of intelligence to make the content as informative as possible, through interviews with sequencing experts. We also ran a webinar, titled Exploring the Current Sequencing Landscape, to facilitate a discussion between experts in the industry and enable the audience to be a part of the conversation.
We would like to give a special thanks to our contributors for their help and guidance in putting this report together:
- Adam Ameur,Associate Professor, SciLifeLab National Genomics Infrastructure, Uppsala University
- Andrew Beggs, Academic & Scientific Lead for Genomics, Birmingham Health Partners
- Darren Griffin, Professor of Genetics, University of Kent
- David Baker, Head of Sequencing, Quadram Institute
- David Smith, Emeritus Professor, Mayo Clinic
- Eddy de Boer, Researcher and PhD Student, University Medical Center Groningen
- Floriana Manodoro, Higher Scientific Officer, Institute of Cancer Research
- Leah Catchpole, Genomics Pipeline Team Leader, Earlham Institute
- Luciano Martelotto, Head of the Single Cell and Spatial Omics Laboratory, Australian Center for Epigenetics, South Australian ImmunoGenomics Cancer Centre
- Luis Zapata Ortiz, PhD Institute of Cancer Research Fellow, Institute of Cancer Research
- Miten Jain, Assistant Research Scientist, University of California, Santa Cruz
- Natalie Thorne, Innovation and Technology Lead, Melbourne Genomics Health Alliance
- Paola Niola, Senior Applications Specialist, UCL Genomics
- Shawn Baker, Genomics Start-up Advisor/Investor/Consultant, SanDiegOmics
- Tamas Korcsmaros, Senior Lecturer, Imperial College London
- Tara Paton, Service Manager for Genotyping, Sanger and Next Generation Sequencing, The Centre for Applied Genomics
- Tatiana Borodina, NGS Unit Team Leader, Max Delbrück Center for Molecular Medicine
- Tiffany Boughtwood, Managing Director, Australian Genomics
- William Scott,Wellcome Trust Clinical Research Career Development Fellow and Honorary Consultant in Endocrinology and Diabetes, Imperial College London
Sequencing Buyer’s Guide content
Chapter 1: Preparing for NGS
This chapter will provide an overview of the steps typically involved in sample prep and provide information to help you choose the right kits for your NGS needs.
Chapter 2: What sequencing technologies are available?
This chapter will give an overview of some of the sequencing platforms currently on the market, with hard facts and figures.
Chapter 3: How to choose the right sequencing technology
This chapter will explain several of the factors that need to be considered before picking an NGS platform to use, including tips from our expert contributors.
Chapter 4: Could out-sourcing NGS be a better option?
This chapter will help to evaluate whether out-sourcing NGS to a facility could be more beneficial than purchasing sequencing equipment for specific workflows.
Chapter 5: Single-Cell and Spatial Sequencing
This chapter will explore the reasons why single-cell sequencing can be so beneficial and provide information about single-cell multi-omics, spatial transcriptomics and single-cell long-read sequencing.
Chapter 6: Innovation in the sequencing space
This chapter will explore the avenues that are enabling scientists to enhance the resolution of NGS, including improvements in long-read sequencing, single-cell technologies, spatial information and combining different omics layers.
Chapter 7: Dealing with NGS data
This chapter will highlight some of the methods and tools used to analyse and store genomic data, in the hope of providing some clarity to this multifaceted, but very important, landscape.
Chapter 8: Making NGS accessible
This chapter will explore the equitability of NGS technologies and speculate on how the field could be balanced out in the future.
Chapter 9: ESG in Genomics
This chapter has been included to provide information about how sequencing companies can improve their ESG performance and to encourage buyers to think about sustainability, both in terms of their own NGS practices, and the companies that they purchase from.
Chapter 10: Planning for shifts in the NGS market
This chapter will explore who the main players are in the NGS market and discuss what the future of the sequencing landscape may look like with important patents running out imminently.
Chapter 11: What does the future of NGS hold?
This chapter will give a brief overview of some of the possible changes of shifts that could occur in the sequencing landscape over the next decade, and explore what they might mean for genomics research.